Unspected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 6, 1997, Pages 831-836

  Fink, Bruno ^a   Bassenge, Eberhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

cGMP; Dog; Low molecular weight thiols; Reactive oxygen species; Reduced intracellular thiols

Indexed keywords

ASCORBIC ACID; CYCLIC GMP; GLYCEROL NITRATE; PENTAERYTHRITYL TETRANITRATE; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE; THROMBIN; NITRIC OXIDE; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOG; DRUG EFFICACY; DRUG TOLERANCE; HEMODYNAMIC PARAMETERS; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASODILATATION; ANIMAL; DRUG EFFECT; FEMALE; MALE; METABOLISM; MOTOR ACTIVITY; THROMBOCYTE;

ANIMALS; ASCORBIC ACID; BLOOD PLATELETS; CYCLIC GMP; DOGS; DRUG TOLERANCE; FEMALE; MALE; MOTOR ACTIVITY; NITRIC OXIDE; PENTAERYTHRITOL TETRANITRATE; PLATELET ACTIVATION; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS; VASODILATOR AGENTS;

EID: 0031283445     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199712000-00020     Document Type: Article

References (33)

1. Bassenge E, Zanzinger J. Nitrates in different vascular beds, nitrate tolerance, and interactions with endothelial function. Am J Cardiol 1992;70:23-9B.
2. Münzel T, Holtz J, Mülsch A, Stewart DJ, Bassenge E. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 1989;79:188-97.
3. Münzel T, Mülsch A, Holtz J, Just H, Harrison DG, Bassenge E. Mechanisms of interaction between the sulfhydryl precursor L-methionine and glyceryl trinitrate. Circulation 1992;86(3):995-1003.
4. Parker JD, Farrell B, Fenton T, Cohanim MA, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-45.
5. Rudolph W, Dirschinger J, Kraus F, Reiniger G, Hall D. Nitrate therapy in patients with coronary artery disease, preparations and doses with and without development of tolerance. Z Kardiol 1990;79(suppl III):65.
6. Bassenge E, Fink B. Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn Schmiedebergs Arch Pharmacol 1996;353:363-7.
7. Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A 1995;92:5244-8.
8. Skatchkov M, Larina L, Larin A, Fink N, Bassenge E. Urinary nitrotyrosine content as a marker of peroxynitrite-induced tolerance to organic nitrates. J Cardiovasc Pharmacol Ther 1997;2:85-96.
9. Sommer O, Fink B, Bassenge E. Platelet-vessel-wall Interactions in the coronary system of hypercholesterolemic guinea pigs [Abstract]. FASEB J 1997;11:A312.
10. Dück KD, Richard F. Langzeitnitrattherapie bei Koronarer Herzkrankheit - Wirkungsverlust durch Toleranzentwicklung? (Long-term therapy of coronary artery disease - loss of efticacy through development of tolerance?). Z Gesamte Inn Med 1990; 24:736-41.
11. Engelmann L, Wetzler G, Kucher A, Frömmel H. Entwicklung und Stand der Nitrattherapie in der DDR (development and state of the art of nitrate therapy in the German Democratic Republic). Z Kardiol 1989;78:99-101.
12. Dikalov S, Skatchkov M, Fink B, Sommer O, Stalleicken D, Bassenge E. Formation of reactive oxygen species and nitrate tolerance are caused by all nitrovasodilators except PETN [Abstract]. FASEB J 1997;11:A10.
13. Dikalov S, Skatchkov M, Bassenge E. Quantification of peroxynitrite, superoxide, and peroxyl radicals by a new spin trap hydroxylamine 1-hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine. Biochem Biophys Res Commun 1997;230(1):54-7.
14. Bassenge E, Fink B. Suppression of nitrate induced tolerance by vitamin C and other antioxidants. The biology of nitric oxide. Part 5. London: Portland Press Ltd., 1996:198.
15. Stewart DJ, Elsner D, Sommer O, Holtz J, Bassenge E. Altered spectrum of nitroglycerin action in long-term treatment: nitroglycerin-specific venous tolerance with maintenance of arterial vasodepressor potency. Circulation 1986;74:573-82.
16. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50.
17. 2+ and on aggregation of human platelets. Eur J Pharmacol 1993; 244:37-47.
18. Schröder H, Schrör K. Organische Nitrate und Thrombozytenfunktion. Haemostaseologie 1988;8:90-9.
19. Campbell JH, Campbell GR. Vascular smooth muscle cells in culture. In: Campbell JH, Campbell GR, eds. Vascular smooth muscle cells in culture. FL: CRC Press, 1987:15-21.
20. Fishman AP. Endothelium: a distributed organ with diverse capabilities. Ann N Y Acad Sci 1982;401:1-8.
21. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-31.
22. Haj-Yehia AI, Benet LZ. Dissociation of tissue thiols content from nitroglycerin-induced cyclic-3′,5′-guanosine monophosphate and the state of tolerance: in vivo experiments in rats. J Pharmacol Exp Ther 1995;273:94-100.
23. Needleman P, Jakschik B, Johnson EMJ. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973;187:324-31.
24. Briner VA, Tsai P, Schrier RW. Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol 1993;264:F322-7.
25. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, Sugishita Y. Platelet cyclic GMP - a potential useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993;88:29-36.
26. Haj-Yehia AI, Benet LZ. In vivo depletion of free thiols does not account for nitroglycerin-induced tolerance: a thiol-nitrate interaction hypothesis as an alternative explanation for nitroglycerin activity and tolerance. J Pharmacol Exp Ther 1996;278:1296-305.
27. Buschmann M, Wiegand A, Schnellbacher K, et al. Comparison of the effects of two different galenical preparations of glyceryl trinitrate on pulmonary artery pressure and on the finger pulse curve. Eur J Clin Pharmacol 1993;44:451-6.
28. Diodati J, Theroux P, Latour JG, et al. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug: importance of adequate heparin dosage in arterial angioplasty in a porcine model. Am J Cardiol 1988;78:654-60.
29. Chen LY, Mehta P, Mehta JL, et al. Platelet inhibitory effect of nitroglycerin in platelet-rich plasma: relevance of glutathione-S-transferases in plasma: sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Invest Med 1996; 28:432-8.
30. Weber AA, Neuhaus T, Seul C, et al. Biotransformation of glyceryl trinitrate by blood platelets as compared to vascular smooth muscle cells. Eur J Pharmacol 1996;309:209-13.
31. Deneke SM, Fanburg BL. Regulation of cellular glutathione. [Review]. Am J Physiol 1989;257:L163-73.
32. Meister A. Commentary on the antioxidant effects of ascorbic acid and glutathione. Biochem Pharmacol 1992;44:1905-15.
33. Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995;25:763-73.